Background: Few studies have examined the associations of serum magnesium (Mg) 
INTRODUCTION
As a cofactor in hundreds of enzymatic reactions in the human body 1 , magnesium (Mg) plays a significant role in multiple biological systems. Low Mg level has been associated with increased risk of chronic diseases in prospective studies, including cardiovascular disease (CVD) 2, 3 , type 2 diabetes [4] [5] [6] [7] [8] , metabolic related diseases 9, 10 , and colorectal cancer 11 . Mechanistic evidence supports a role for magnesium in cardiovascular diseases, including on blood pressure 12 , oxidative stress 13 , endothelial function 14 and thrombosis 15 , and arrhythmia 16 . Additionally, Mg supplementation may improve glucose induced insulin response and insulin-mediated glucose disposal among nondiabetic participants 17, 18 Although multiple lines of evidence support a role of Mg in major chronic diseases, few longitudinal studies have examined the relationship between serum Mg and mortality. One study, based on data from NHANES I Follow-up Study 1971-75, examined the effects of serum Mg on risk of CVD and all-cause mortality and observed an inverse association between serum Mg and mortality from all cause and CVD in participants followed up through 1992 19 . Recently, the NHANES I mortality follow-up has been extended to include deaths events through a longerterm follow-up period, providing more than double the number of mortality cases (n = 9012) to enable us to not only evaluate associations with all-cause mortality, but also cause-specific mortality, including cancer and stroke. We hypothesize that the population with low serum Mg levels have a high risk of mortality.
METHODS

Study design and population
We used data from the NHANES I 1971-1975, a multistage national probability survey, designed to evaluate the health and nutritional status of US general population 20 . Among the representative sample of 32,000 US civilians selected, 14,407 participants at NHANES I (aged 25-74 years) with complete medical examinations were included in a longitudinal follow-up study, NHEFS, in 1982 21 . The baseline information for NHEFS, including demographic and socioeconomic information and physical and laboratory examinations, was provided by NHANES I. After excluding 54 participants with missing measures of serum Mg, we finally included a total of 14,353 participants in the analysis. The design of the NHANES has been reviewed and approved by Institutional Review Board at the Centers for Disease Control and
Prevention. All subjects provided written informed consent.
Outcome measures
The NHEFS cohort study included four waves of follow-up periods in 1982-1984, 1986, 1987, and 1992 . The follow-up data contained information on health-related outcomes. Vital status was assessed and confirmed by proxy interviews, medical records, and death certificate through the National Death Index. New record linkages of NHEFS participants to death records through December 31, 2011 were conducted by National Center for Health Statistics 22, 23 . Our primary outcomes included all-cause, CVD, cancer, and stroke mortality. Causes of mortality were divided into four categories using the Tenth Version of the International Classification of Diseases (ICD-10): cancer (C00-97), CVD (I00-78), ischemic heart disease (CHD) (I58-63), and stroke (I60-69) deaths.
Baseline Mg measurements
Non-fasting blood samples were collected and frozen and then sent to the Centers for Disease Control and Prevention for biochemical assays. Serum Mg concentrations were determined during the baseline survey by atomic absorption spectrophotometry using the method of Hansen and Freier 24 . Quality control samples were analyzed with every 20 specimens, and the repeat limits were below 1.40 and above 2.10 mEq/L 25, 26 . We converted the unit of "mEq/L" for serum Mg concentrations into "mmol/L" for this study.
Confounders
Covariates were measured at baseline, including age, sex, race, body mass index (BMI) (kg/m 2 ), education (≥ high school degree, or < high school degree), alcohol intake (> 2 times per week, or < 2 times per week), levels of recreational and non-recreational physical activity (selfreport of being very active, moderately active, or quite inactive), smoking (never, former current), sitting blood pressure (mmHg), history of diabetes (self-reported physician diagnosed diabetes, or use of hypoglycemic medication), history of hypertension (self-reported physician diagnosis, or taking antihypertensive drugs), history of CVD (self-reported physician diagnosed heart failure, heart attack, stroke, or possible heart or circulatory troubles), serum calcium and cholesterol levels, and intake of vitamin or mineral supplements (self-reported any vitamin or mineral supplementation within last 30 days before the interview).
Statistical analysis
We estimated the hazard ratios (HRs) and 95% confidence intervals ( All statistical analyses were conducted by using SUDAN and SAS software (version 9.4; SAS Institute). For all analyses, P < 0.05 for 2-tailed tests was considered statistically significant.
RESULTS
Baseline Characteristics and Distribution of Serum Mg Concentrations
In (TABLE 1) . After adjusted for potential confounders, women, non-white participants, current smokers, vitamin/mineral supplement users, or participants with diabetes, hypertension, or low levels of total cholesterol were more likely to have low serum Mg, respectively (TABLE 2).
All-cause mortality
During a median 28.6 years of follow-up, a total of 9,012 deaths (63%) among 14,353 participants occurred. Among the 9,012 deaths, 3,959 (42%) were due to CVD, 1,923 (23%) due to cancer, and 708 (7%) due to stroke. Of stroke deaths, 542 (72%) died from ischemic stroke, 125 (21%) from cerebral stroke, and 41 (7%) from other stroke. The mean age at death was 75 years and the mean baseline serum Mg levels before death was 0.85 mmol/L. Nearly 50% of all deaths occurred in women, 29% were hypertensive participants, 6% had diabetes mellitus, and 14% had CVD. (TABLE 3 ). An L-shaped curve was shown between serum Mg and all-cause mortality after adjusting for potential confounders (FIGURE 2). We did not detect any significant association between serum Mg levels and mortality after serum Mg levels reached 0.70 mmol/L.
Cause-specific mortality
After adjustment of age, sex, and race, participants with serum Mg levels < 0.70 mmol/L had a 57% and 58% higher risk of CVD and CHD mortality comparing to those with serum Mg levels of 08-0.89 mmol/L. However, these associations were not statistically significant after further adjusting for history of diabetes and hypertension ( Previous observational studies have linked low Mg levels and chronic diseases 2-8, 11 , which are major contributors to all-cause mortality and cause-specific mortality in the US. We found that there were decrease trends in both SBP/DBP levels and prevalence of diabetes and hypertension as serum Mg increased. And participants with hypertension or diabetes were more likely to be with Mg deficiency, the risk was twice higher than general population. To minimize residual confounding due to these diseases, we controlled for history of hypertension, diabetes mellitus, BMI, and vitamin/mineral supplements use in our multivariate model. Moreover, subgroup analyses stratifying by these factors were also conducted, but no significant interactions were detected. Although history of diabetes, CVD, and hypertension did not significantly modify the relation of serum Mg with mortality, the association was strengthened in the general population after excluding those with these diseases.
In this study, we observed an association of low serum Mg levels with all-cause and CVD mortality in men only. Meanwhile, the average Mg levels in men were 0.02 mmol/L higher than that in women. And the prevalence of Mg < 0.70 mmol/L was 50% lower in men than in women in our study. Consistent with our findings, a pooled analysis of two large population-based cohort studies of Chinese adults showed that low circulating Mg levels were associated with to high risks of all-cause mortality and CHD mortality only in men 52 . An elevated risk for mortality with low Mg was also found in a cohort of 4,035 men aged 30-60 years in France 53 .
Similarly, inverse association between circulating Mg and ischemic heart disease was only reported among studies with more male participants (percentage of male ≥ median) in a metaanalysis 2 . As a mechanism for potential between-gender differences in the pathophysiology of low serum Mg on disease risk is unclear, this finding may be due to chance. In any case, these findings warrant further study.
We also found that Mg deficiency was associated with a twice higher risk of all-cause mortality among smokers than non-smokers. These findings are consistent with risks from Mg deficiency among smokers reported in several epidemiological studies [54] [55] [56] . Poor Mg status, together with long-term exposure to thiocyanate anions among smokers, accelerates the atherosclerotic processes in animal models 57 . Moreover, a randomized clinical trial found that
Mg deficiency accelerates the development of nicotine addiction through increasing the Mg dependent N-Methyl-D-aspartic acid or N-Methyl-D-aspartate receptors activity 58 . Our findings, combined with these studies, suggest that a possible interplay between low serum Mg and smoking might amplify the effects of each risk factor alone on disease risk.
Our study has several major strengths. Our use of NHANES data provided large nationally representative sample of the US adult population, increasing generalizability. The long follow-up and large number of cases (n > 9000) in our study increased statistical power. While dietary Mg has some limitations due to collinearity with dietary potassium, and recall bias introduced by using food frequency questionnaire, both of these limitations do not apply to serum Mg. Our examination of cause-specific mortality, and dose-response relationships using splines, represents the largest and most in-depth examination of the association of serum Mg and mortality yet conducted.
Several limitations merit consideration. First, given the nature of the observational studies, we cannot draw conclusions on causal relations between serum Mg and mortality.
Second, the influence of possible change in Mg status on mortality risk cannot be assessed in the lack of longitudinal measurements of serum Mg. This gap needs to be addressed in future studies. Finally, the possibility of residual confounding due to unmeasured/ poorly measured factors or time-varying factors cannot be excluded.
In conclusion, our results from a large, nationally representative, and prospective study indicated that baseline serum Mg at a low level of < 0.70 mmol/L was significantly associated with an increased risk of all-cause mortality in US adults over an average follow-up of 28 years.
Our findings support the hypothesis that serum Mg may be clinically useful for predicting longterm health outcomes and mortality in the general population.
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